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5-fluorouracil (5-FU) is a potent antineoplastic agent used for the treatment of 
various malignancies. The L-arginine nitric oxide (NO) pathway involved in the 
pathogenesis of chemotherapy induced kidney damage. This work investigated 
the beneficial mechanism of L-arginine supplementation in 5-FU induced nephro-
pathy. Eighty male Wistar rats were divided into four equal groups: control group; 
L-arginine group (378 mg/rat/day for 4 weeks); 5-FU group (189 mg/rat/week for 
4 weeks) and L-arginine for 1 week before and 4 weeks concomitant with 5-FU 
group. At the end of experiment, the kidney functions were assessed and kidneys 
specimens were processed for paraffin sections and stained with haematoxylin and 
eosin (H&E), Masson’s trichome (MT) and periodic acid-Schiff (PAS) stains. Other 
sections were processed for immunohistochemical demonstration of caspase-3 
and inducible NO synthase (iNOS). Image analyser was used to analyse the re-
sults morphometrically and statistically. L-arginine administration to 5-FU treated 
animals elicited significant reduction in serum urea and creatinine levels, urine 
volume, urinary protein excretion and kidney/body weight ratio in comparison to 
fluorouracil treated group. L-arginine improved glomeruloscelerosis, degeneration 
of convoluted tubules and interstitial fibrosis in 5-FU treated animals. L-arginine 
attenuated effectively some biochemical and histological changes in 5-FU nephro-
toxicity. (Folia Morphol 2017; 76, 4: 608–619)
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INTRODUCTION
Anticancer drugs under ideal circumstances would 
eliminate cancer cells without damaging normal tissues. 
However, no agents now available are completely devoid 
of toxicity [11]. 5-fluorouracil (5-FU) is regarded as the 
widespread agent in the management of colorectal 
cancer [13] and it’s got activity against many solid tu-
mours, including cancers in the breast, stomach, pan-
creas, oesophagus, liver, head and neck, and anus [11]. 
Although, 5-FU generated acceptable outcome, it was 
considered a nephrotoxic compound [25]. Moreover, it 
is a pyrimidine fluorinated analogue and classified as 
being an antimetabolic agent that inhibits the synthesis 
of both DNA and RNA in normal and tumour cells [42].
L-arginine is really a semi essential amino acid and 
is thought to be a principle source for nitric oxide 
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(NO) generation through NO synthase (NOS) [29]. 
This temporary molecule (NO) may play a crucial 
role in regulating kidney function in normal and 
pathological conditions [14]. Three NOS isoforms 
have been expressed in the kidney [16]. Endothelial 
NOS (eNOS) has a role in regulation of renal blood 
flow. Neuronal NOS (nNOS) is found mainly in the 
macula densa and has a role in secretion of renin. 
Inducible NOS (iNOS) is found in the kidney in patho-
logically affected mesangium and tubules [33]. The 
physiological importance of iNOS in kidney tubules 
is unclear [15].
In many studies exogenous L-arginine may protect 
renal tissue against toxic or ischaemic injury [39]. 
L-arginine/NO pathway defects are already suggested 
to have a main role in the pathogenesis of kidney af-
fection. The renoprotective effect of L-arginine was 
postulated due to increased total renal blood flow 
and NO content [28]. Although many experimental 
studies have been performed on the renoprotective 
effect of L-arginine with conflicting results, there are 
limited studies on histological and immunohisto-
chemical basis of this effect. 
Based on all previous observations, the present 
study investigated on biochemical, histological and 
immunohistochemical basis the possible beneficial 
influence of L-arginine on nephrotoxicity caused by 
5-FU administration in rats.
MATERIALS AND METHODS
Ethical approval
The procedures were conducted in accordance with 
guidelines and protocols reviewed and approved by the 
ethical committee for animal care and use in King Fahd 
Medical Research Centre (KFMRC), KAU, Jeddah, Saudi 
Arabia, which are in accordance with the guidelines of 
the Canadian Council on Animal Care.
Drugs
— 5-fluorouracil (Biosynth Company): was supplied 
in the form of ampoules of 250 mg and intraperi-
toneally injected at 189 mg/rat/week [18, 34]. 
— L-arginine was purchased from Sigma-Aldrich 
Chemicals Co. (St. Louis, Missouri, USA). L-ar-
ginine solution was prepared by dissolving 40 g 
of L-arginine in 100 mL of normal saline to 
obtain concentration of 378 mg/0.9 mL and 
given orally. The calculated dose of L-arginine 
was based on preliminary data [5, 31] on its 
nephroprotective effect.
Animals
Eighty adult male Wister albino rats (190–210 g) 
were chosen for the study. They were maintained un-
der normal laboratory conditions, and were received 
free access of normal laboratory chow and water ad 
libitum. Rats were acclimatised for a week before 
beginning the experiment.
Experimental protocol
Rats were randomly divided into four groups 
(20 rats each):
— Group I (control group): received intraperitoneal 
injection (IP) of normal saline solution (3.78 mL/ 
/week) for 4 weeks [18, 34];
— Group II (L-arginine group): received oral L-argi-
nine (378 mg/rat/day) for 4 weeks [5, 31];
— Group III (5-FU group): received IP of 5-FU 
(189 mg/rat/week) for 4 weeks [18, 34];
— Group IV (L-arginine group + 5-FU group): was 
treated with L-arginine (378 mg/rat/day) starting 
1 week before 5-FU which was given at the same 
dose, route and period as group III.
By the end of treatment, blood samples were 
collected from the tail vein of experimental groups 
and the serum was separated from each sample for 
assessing total proteins, albumin, urea and creatinine 
levels. Also the urine volume (mL/24 h) and urinary 
protein excretion (mg/24 h) were estimated.
Absolute and relative kidney weight
The mean weight of the rats was recorded; then 
the animals were sacrificed by decapitation. The ani-
mals were dissected and their kidneys were separated 
and weighed. Absolute and relative organ weights 
were determined.
Histological and immunohistochemical techniques
The right kidneys were separated and immediately 
fixed in 10% buffered formalin and processed for 
preparing histological sections 5 µm thick. They were 
stained with haematoxylin and eosin (H&E) and Mas-
son’s trichrome (MT) stains and periodic acid-Schiff’s 
reaction (PAS) [8].
Other sections were immunohistochemically 
stained by avidin-biotin peroxidase method for de-
tection of caspase-3 and iNOS expression [7]. Briefly, 
sections were deparaffinised, hydrated and then 
incubated overnight with the mouse monoclonal 
primary antibody to caspase-3 (Ab-7, Mouse Mab. 
MS.) at a dilution of 1:500 or rabbit polyclonal pri-
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mary antibody specific for iNOS enzyme (SC-650, 
Santa Cruz Biotechnology) at a dilution of 1:1000.
Using a universal detection kits (Dakocytomation), 
biotinylated secondary antibodies form a complex 
with peroxidase conjugated streptavidin molecules. 
Sections were rinsed in phosphate buffered saline 
and few drops of biotinylated secondary antibodies 
were applied for 15 min. Then, sections were rinsed 
and treated with the prepared diaminobenzidine 
tetra-hydro chloride (DAB) substrate chromogen 
solution for 15 min until the desired brown colour 
obtained. Finally, sections were counterstained with 
Mayer’s haematoxylin. 
Morphometric studies
Morphometric measurements were done using 
Image-Pro Premier system. Glomerular sclerosis was 
assessed as incremental degrees of PAS positive ma-
terials, obliteration of capillary lumina and the pres-
ence of amorphous hyaline material and scored based 
on the criteria of Romero et al. [35]. A minimum 
40 glomeruli were randomly examined in every speci-
men with a magnification of ×400 using Image-Pro 
Premier image analysis software. Sclerosis involving 
greater than 80% in the glomerular tuft was consid-
ered global, and sclerosis involving lower than 80% 
was considered segmental. Data are expressed as 
the percentage of glomeruli showing segmental or 
global sclerosis.
The average percentages of scored histopathologi-
cal lesions of renal tissues such as tubular damage 
and atrophy, tubulo-interstitial infiltration and inter-
stitial fibrosis were recorded according to the criteria 
of Romero et al. [35]. The degree of injury includes 
five scores depending on the ratio of affected area 
to total area of the section in the field of vision: 
0 — affected area < 10%, 1 — 10% < affected area 
< 20%, 2 — 20% > affected area < 40%, 3 — 40% 
> affected area < 60%, 4 — 60% < affected area 
< 80%, 5 — affected area > 80%. The mean score 
from 10–15 sections of each specimen were recorded.
The area per cent of caspase-3 and iNOS im-
muno-stained slides was studied and compared 
among the different groups used in this study. The 
area per cent of the immunostaining was measured 
in 10 microscopic fields (original magnification, 
× 200) for every animal and the mean values were 
calculated.
Statistical analysis
Comparison between different groups was sta-
tistically done using one way analysis of variance 
(ANOVA) and then by multiple comparison test to 
evaluate the main difference between various groups. 
Differences were considered statistically significant 
when p < 0.05. 
RESULTS
Effect on BW, KW and relative KW to BW (Table 1)
Fluorouracil treated rats (group III) had significant-
ly lower body weight (BW) than controls. However, 
fluorouracil treated rats that additionally received 
L-arginine (group IV) were significantly heavier than 
the rats receiving fluorouracil alone. There was no 
significant difference between L-arginine (group II) 
and control groups. 
Moreover, a significant increase in kidney weight 
(KW) was shown in fluorouracil treated group. Ani-
mals co-treated with both L-arginine and fluorouracil 
showed a significant reduction in KW in comparison 
with fluorouracil treated group (group III).
There was a significant increase in KW to BW 
(KW/BW) ratio in the fluorouracil group (p < 0.05). 
L-arginine treatment in group IV decreased KW/BW 
ratio compared to fluorouracil group as shown in 
Table 1. 
Table 1. Body weight, absolute and relative kidney weight (KW/BW) of fluorouracil-treatment with or without L-arginine
BW [g] KW [g] KW/BW
Group I 295.5 ± 3.4 1.18 ± 0.10 0.40 ± 0.02
Group II 303.0 ± 6.1 1.15 ± 0.08 0.38 ± 0.04
Group III 218.5 ± 5.3*† 1.67 ± 0.09*† 0.76 ± 0.05*†
Group VI 283.9 ± 5.4# 1.26 ± 0.09# 0.44 ± 0.03#
Data are represented as mean ± standard deviation (n = 6); p < 0.05 was considered significant
*A significant change in comparison with control (group I)
†A significant change in comparison with L arginine group (group II)
#A significant change in comparison with fluorouracil group (group III)
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Biochemical changes
Effect on serum total proteins, albumin, urea 
and creatinine levels. Table 2 illustrates serum to-
tal proteins, albumin, urea and creatinine levels in 
rats receiving fluorouracil treatment with or with-
out L-arginine. Fluorouracil-treated rats exhibited 
a considerable increase in serum urea and creati-
nine levels compared with apparent depletion of 
serum total protein and albumin contents. However, 
fluorouracil-treated group protected by L-arginine 
supplementation showed marked amelioration but 
was still below the normal value. 
Effect on urine volume (mL/24 h) and urinary 
protein excretion (mg/24 h) (Table 3). In experi-
mental group treated with fluorouracil, there was 
a detected increase in 24 h urine volume and total 
urinary protein in comparison with the control group. 
However, L-arginine treatment of fluorouracil-intox-
icated rats led to marked amelioration but was still 
not matched with the control animals. 
N.B. No significant difference was detected be-
tween control untreated and L-arginine-treated con-
trols at all parameters.
HISTOLOgICAL RESULTS
Group I (control group). The control kidney 
had normal histological architecture, Examination 
of H&E stained sections of kidneys of this group 
showed that the renal corpuscle was formed of 
a glomerular tuft of blood capillaries surrounded by 
the Bowman’s capsule which had a parietal layer 
lined with simple squamous epithelium and inner 
concave visceral layer lined by round podocyte cells 
with deeply stained nuclei. In between the two lay-
ers there was a capsular space or (urine space). The 
proximal convoluted tubules had narrow lumen oc-
cupied by striated brush borders and a regular basal 
lamina lined by a single layer of pyramidal cells with 
eosinophilic cytoplasm and central rounded nuclei. 
Distal convoluted tubules lined by a relatively large 
number of cuboidal epithelial cells. The lumens of 
the distal tubules were wider than the proximal tu-
bules and their cytoplasm was less acidophilic and 
the nuclei were rounded (Fig. 1A).
Collagen fibres were found to be of minimal 
amounts and were confined to the Bowman’s cap-
sule, around the tubules and basal laminae of glo-
merular capillaries (Fig. 1B).
PAS positive materials were seen in the basement 
membrane of renal tubules in addition to the brush 
border of the proximal convoluted tubules. Intra-
glomerular PAS positive material was also detected 
(Fig. 1C).
Group II (L-arginine group). The renal architec-
ture in L-arginine treated animals exhibited normal 
histological architecture with no changes detected in 
this group as compared to group I (Fig. 2A). Collagen 
fibre distribution and PAS positive areas were also 
similar to control sections (Fig. 2B, C).
Group III (fluorouracil group). In fluorouracil 
treated rats, areas of glomerular and tubular degen-
Table 2. Renal function markers of rats treated with fluorouracil with or without L-arginine
Albumin [g/dL] Total proteins [g/dL] Creatinine [mg/dL) Urea [mg/dL]
Group I 3.42 ± 0.13 6.0 ± 0.3 0.62 ± 0.20 33.62 ± 0.13
Group II 3.47 ± 0.17 7.0 ± 0.5 0.65 ± 0.07 33.57 ± 0.17
Group III 2.13 ± 0.18*† 4.1 ± 1.5*† 1.10 ± 0.12*† 85.13 ± 0.18*†
Group VI 3.35 ± 0.04# 7.3 ± 1.1# 0.75 ± 0.06# 35.33 ± 0.04#
Data are represented as mean ± standard deviation (n = 6); p < 0.05 was considered significant
*A significant change in comparison with control (group I)
†A significant change in comparison with L-arginine group (group II)
#A significant change in comparison with fluorouracil group (group III)
Table 3. Urine volume and urinary proteins excretion in rats 
treated with fluorouracil with or without L-arginine
Urine volume  
[mL/24 h]
Urinary proteins  
[mg/24 h]
Group I 11.4 ± 0.9 6.0 ± 0.4
Group II 12.3 ± 0.8 7.0 ± 0.7
Group III 29.0 ± 2.3*† 24.1 ± 1.5*†
Group VI 15.3 ± 3.4# 5.8 ± 1.1# 
Data are represented as mean ± standard deviation (n = 6);  
p < 0.05 was considered significant  
*A significant change in comparison with control (group I) 
†A significant change in comparison with L-arginine group (group II) 
#A significant change in comparison with fluorouracil group (group III)
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Figure 1. Photomicrographs of sections in the kidney of a control rat (group I) showing: (A) Normal renal architecture: glomerulus (G), proxi-
mal (P) and distal (D) convoluted tubules haematoxylin and eosin (H&E), scale bar = 20 µm; (B) Normal distribution of collagen fibres in the 
glomerulus (G), Bowman’s capsule and surrounding the tubules (arrows) Masson’s trichrome, scale bar = 50 µm; (C) strong periodic acid-
-Schiff (PAS) reaction in the glomeruli (G), brush border of the proximal convoluted tubules (P), basal lamina (arrows) of tubules PAS, scale  
bar = 20 µm.
Figure 2. Photomicrographs of sections in the kidney of L-arginine treated rat (group II) showing: (A) Normal pattern of renal architecture 
haematoxylin and eosin (H&E), scale bar = 20 µm; (B) Normal distribution of collagen fibres in the glomeruli, and surrounding the tubules 
Masson’s trichrome, scale bar = 50 µm; (C) Strong periodic acid-Schiff (PAS) reaction in the glomeruli (G), brush border of the proximal  
convoluted tubules (P) and basal laminae of tubules (arrow) PAS, scale bar = 20 µm.
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Figure 3. Photomicrographs of sections in the kidney of a fluorouracil treated rat (group III) demonstrating: (A) Dilated and congested glo-
merular capillary loops (G) and vacuolisation of tubular epithelial cells (T). Homogenous eosinophilic casts are seen in some tubules (arrows) 
haematoxylin and eosin (H&E), scale bar = 20 µm; (B) Dilated and congested blood vessels and interstitial haemorrhages (arrows) H&E, 
scale bar = 100 µm; (C) Extensive interstitial mononuclear infiltrating cells (IF) surrounding destructed tubules H&E, scale bar = 50 µm; (D) 
Increased intraglomerular and peritubular collagen deposition Masson’s trichrome, scale bar = 50 µm; (E) Increased intraglomerular periodic 
acid-Schiff (PAS) positive material. Most of proximal convoluted tubules shows weak reaction in their brush border (P) with focal interstitial 
strong reaction (IT) PAS, scale bar = 20 µm.
eration were seen among apparently normal ones. 
The epithelial lining of the affected tubules showed 
either pyknotic or vacuolated degeneration. Their 
tubular lumina appeared swollen with the presence 
of cellular debris. Hyaline casts were also observed 
within some tubular lumina (Fig. 3A). There were 
different patterns of glomerular damage such as glo-
merular atrophy, lobulation and glomerular sclerosis. 
Interstitial and periglomerular leukocytic infiltrations 
were detected (Fig. 3B, C). Dilated and congested 
glomerular capillaries were also seen (Fig. 3A). The re-
nal cortex and medulla exhibited multiple congested 
capillaries, interstitial mononuclear cellular infiltration 
and extravasated blood cells (Fig. 3B, C).
Masson trichrome stained sections revealed in-
creased intraglomerular and peritubular collagen 
fibres (Fig. 3D).
The glomerular mesangium was mostly expanded 
by increase of intraglomerular PAS positive material. 
Some tubules showed strong PAS reaction in their 
basal laminae while others revealed weak PAS reaction 
in their brush border. Few areas of interstitial tissue 
showed intense reaction (Fig. 3E).
Group IV (L-arginine + fluorouracil group). L-ar-
ginine supplementation to fluorouracil-treated group, 
showed improvement majority of renal corpuscles had 
narrow urinary space, regular glomerular cellularity. 
The proximal convoluted tubules cells showed vesicular 
rounded basal nuclei with acidophilic granular cytoplasm 
and characteristically narrow lumen. The distal convo-
luted tubules showed less acidophilic cytoplasm and 
characteristically wide lumen (Fig. 4A). Normal pattern of 
collagen fibres in the Bowman’s capsule and around the 
tubules (Fig. 4B) and PAS positive staining structures were 
detected in the glomeruli in the basement membrane of 
the parietal layer of Bowman’s capsules, in the basement 
membrane of renal tubules and in the brush border of 
the proximal convoluted tubules (Fig. 4C). 
Inducible NO and caspase-3 immunohistochemistry
Inducible nitric oxide synthase was immunohisto-
chemically detected in the cytoplasm of the tubular 
cells in control group. Higher expression was seen in 
fluorouracil treated group (group III) which was de-
creased by co-treatment of fluorouracil and L-arginine 
in renal tissues. No detectable difference was seen 
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between group II (L-arginine group) and control rats 
(Fig. 5A–D).
Caspase-3 immunohistochemistry showed nearly 
negative staining affinity in control and L-arginine-
-treatment. However, in experimental group treated 
with fluorouracil, there was an apparent increase 
in caspase-3 cytoplasmic expression, and these was 
markedly reduced in fluorouracil-treated group sup-
plemented L-arginine (Fig. 6A–D). 
Quantitative morphometric results
The quantitative morphometric histological results 
are summarised in Table 4. In group III (fluorouracil 
treated rats), 13.8% of glomerular tuft area was seg-
mentally sclerosed and 2.0% was globally sclerosed. 
L-arginine treatment (group VI) decreased significantly 
the glomerulosclerosis compared to group III. 
Tubular degeneration and atrophy, interstitial cell 
infiltration and interstitial fibrosis were demonstrated 
at a mean score of 4.2, 1.7 and 1.2, respectively 
in group III (fluorouracil group). L-arginine (group IV) 
significantly decreased the mean score of these le-
sions. Meanwhile, no significant difference was de-
tected between groups; II and IV and the control 
group.
The mean area per cent of iNOS immunostaining 
in control sections was 4.112 ± 0.703. It signifi-
cantly increased in group III (fluorouracil group) to 
18.549 ± 1.34. However, nonsignificant difference 
was found in groups II (L-arginine group) and IV 
(L-arginine + fluorouracil group) in comparison to 
control rats; 4.624 ± 0.112 and 5.391 ± 0.230, 
respectively. Moreover, the mean area per cent of 
caspase-3 immunoexpression indicated a highly 
significant increase in group III (12.8 ± 1.17) in 
comparison with control rats (2.5 ± 0.92) and 
a significant decrease in group IV (7.3 ± 0.51) in 
comparison with group III.
DISCUSSION 
5-fluorouracil is a widely used chemotherapeutic 
drug, due to its efficacy in varieties of human malig-
nancies; however, it has hepatotoxic and nephrotoxic 
side effects [21]. This organ toxicity is coupled with 
increased oxidative stress and apoptosis [34]. There-
fore, the current work studied the possible protec-
tive effect of L-arginine treatment as a NO precursor 
against 5-FU induced nephrotoxicity. 
In the present work, animals dissection showed that 
the decrease in body weight induced by 5-FU might be 
Figure 4. Photomicrographs of sections in the kidney of a rat co-treated with fluorouracil and L-arginine (group IV) showing: (A) Within nor-
mal renal architecture haematoxylin and eosin (H&E), scale bar = 20 µm; (B) Within normal distribution of collagen fibres in the glomerulus, 
Bowman’s capsule and surrounding the tubules Masson’s trichrome, scale bar = 50 µm; (C) Strong periodic acid-Schiff (PAS) reaction in the 
glomeruli (G), brush border of the proximal convoluted tubules (P), basal laminae of tubules (arrows) PAS, scale bar = 20 µm.
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Figure 6. Photomicrographs of sections in the kidneys of a control rat (group I) showing nearly negative immunostaining of caspase-3 (A);  
B. L-arginine treated rat (group II) showing very weekly positive immunostaining; C. A fluorouracil treated rat (group III) showing darkly stained 
areas of positive immunoreactions; D. A rat co-treated with fluorouracil and L-arginine (group IV) showing lightly stained areas of immuno-
staining. caspase-3, scale bar = 50 µm.
Figure 5. Photomicrographs of sections in the kidneys of a control rat (group I) showing very weak immunostaining of inducible nitric oxide 
synthase (iNOS) (A); B. L-arginine treated rat (group II) showing mild positive immunostaining; C. A fluorouracil treated rat (group III) showing 
increased area of strong positive iNOS immunostaining; D. A rat co-treated with fluorouracil and L-arginine (group IV) showing moderately 
iNOS positive immunostaining. iNOS, scale bar = 20 µm.
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due to loss of skeletal muscles and adipose tissue. This 
suggestion was also reported by Devlin [19]. In addition, 
a significant rise in relative KW to BW was in agreement 
with the results recorded by Saleh and El-Demerdash [37]. 
This increase in reno-somatic index might be due to 
the oedema of renal parenchyma caused by renal 
inflammation [2]. 
The biochemical findings in this work were in 
agreement with those obtained by El-Hoseany [20] 
and Rashid et al. [34] who reported that 5-FU ad-
ministration led to impairment in kidney function 
as shown by increase in creatinine and urea and 
a significant reduction in total serum proteins and albu- 
min. Nephrotoxicity induced by 5-FU was confirmed 
by histological changes including glomerular and 
tubular degeneration. Homogenous eosinophilic casts 
were seen in some tubules. Dilated and congested 
glomerular capillary loops were frequently observed. 
Obtained results are similar to those recorded previ-
ously by Ali and Al Moundhri [4] and Rashid et al. [34]. 
They confirmed that 5-FU and cisplatin severely 
impaired renal function. 
Presently, treatment with L-arginine starting 1 week 
before 5-FU, apparently reduced its deleterious effects 
and protected the kidney from damage. This protec-
tion was clearly reflected by a significant decrease in 
kidney weights and in KW relative to BW and a rise in 
total serum proteins and albumin. Also, serum urea 
and creatinine returned nearly to its normal levels. 
These findings were also reported by Abo Zeid et al. [1]. 
The authors postulated that L-arginine treatment 
as a NO precursor caused a significant improvement 
of kidney functions in various forms of acute and 
chronic renal injury. The inductive effects of L-arginine 
might be due to a change in the level of endogenous 
NO. This effect was reported to protect against drug 
induced nephrotoxicity such as cyclosporine [31] and 
gentamycin [14] as well as in unilateral ureteral ob-
struction [26]. 
Nitric oxide is synthesized from L-arginine by three 
different isoforms of nitric oxide synthases (NOSs): 
neuronal (nNOS), inducible (iNOS) and endothelial 
nitric oxide synthase (eNOS). As NO has no specific 
receptors, its function and activity in the different 
pathophysiological conditions mainly depend on 
the site and concentration of its production and the 
surrounding mediators. It has a central function in 
neurotransmission, inflammatory processes and in the 
regulation of angiogenesis and vasodilatation [36].
Our immunohistochemical and morphometric 
results showed that iNOS was minimally expressed 
in normal renal tissue and highly expressed in dam-
aged proximal tubule epithelial cells in 5-FU treated 
group. The present study attempted to clarify the 
consequence of modulation of iNOS on the extent 
of 5-FU induced nephrotoxicity by using L-arginine 
as a NO precursor.
Many studies showed that iNOS is low or not 
expressed in normal renal tissues, whereas several 
nephropathies were associated with substantial 
amounts of iNOS in the glomeruli and the renal in-
terstitium [9, 12, 22, 24, 41]. Other studies, however, 
indicated that iNOS is expressed in large amounts 
in the normal renal tissue, localising mainly in the 
tubules, and that pathologic conditions, such as 
clinical and experimental chronic renal insufficiency, 
Table 4. Morphometry of histopathological lesions and immunohistochemical reactions
Group I Group II Group III Group IV
Glomerular sclerosis:
Normal (%) 98.1 ± 0.5 97.3 ± 2.1 84.2 ± 4.1 96.8 ± 1.7
Segmental (%) 1.9 ± 0.13 2.7 ± 0.02 13.8 ± 3.2*† 3.2 ± 0.04#
Global (%) 0.0 0.0 2.0 ± 1.0*† 0.0
Tubular degeneration and atrophy (0–5) 0.0 0.0 4.2 ± 0.10*† 0.0
Interstitial infiltration (0–5) 0.0 0.0 1.7 ± 0.40*† 0.0
Interstitial fibrosis (0–5) 0.0 0.0 1.2 ± 0.31*† 0.0
The mean area per cent of iNOS 4.11 ± 0.7 4.62 ± 0.11 18.55 ± 1.34*† 5.39 ± 0.23#
The mean area per cent of caspase-3 2.5 ± 0.92 3.8 ± 0.02 12.8 ± 1.17*† 7.3 ± 0.51#
Data are represented as mean ± standard deviation; p < 0.05 was considered significant; iNOS — inducible nitric oxide synthase
*p <0.05 in comparison with the control group (group I) 
†p < 0.05 in comparison with the L arginine treated group (group II)
#p < 0.05 in comparison with the fluorouracil treated group (group III)
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are associated with marked iNOS down regulation 
[3, 6, 44]. One possible reason for this disagreement 
is the wide heterogeneity of the experimental mod-
els studied so far. Additional discrepancy may arise 
from the fact that the primary antibodies used to 
detect iNOS come from several sources, because the 
behaviour of different antibodies directed against 
NOS isoforms can vary dramatically according to 
type (monoclonal vs. polyclonal), species in which 
the antibody was raised, and tissue in which the 
antibody is tested [17].
Schneider et al. [38] recorded that the histological 
changes induced by 5-FU might be related to the dep-
rivation of internal L-arginine available for synthesis of 
NOS and subsequent uncoupling of constitutive NOS 
that triggers iNOS induction. The high expression of 
iNOS can be attributed to the compensatory increase 
in its level trying to increase the NO level to counteract 
the deleterious effect of 5-FU on the kidney. However, 
iNOS protein, once induced, produces large amounts 
of NO for a sustained period. This NO acts as a free 
radical and causes cytotoxicity in a variety of cells or 
tissues [15]. In the present work L-arginine improved 
the histological changes and consequently diminished 
the expression of iNOS compared to 5-FU group.
Schwartz et al. [40] reported that up-regulation 
of iNOS may lead to down-regulation of eNOS which 
is responsible for maintaining physiologic renal func-
tions. The iNOS rapidly reacts with superoxide (O2–), 
resulting in the formation of the highly reactive oxi-
dant peroxynitrite (ONOO–) rather than NO under 
conditions of absolute or relative L-arginine deficiency 
[32, 45]. Oxidative stress linked to iNOS is mediated 
via lipid peroxidation and DNA damage [30]. Thus 
L-arginine treatment in the present work could pro-
tect against the tubular and glomerular histological 
changes by inhibiting iNOS activity and preventing the 
formation of ONOO– free radicals and consequently 
prevents the DNA damage induced by 5-FU. 
5-fluorouracil caused strong caspase-3 immu-
nostaining in the renal parenchyma. However, L-ar-
ginine treatment significantly attenuated apoptosis 
in both glomerular and tubular region by inhibiting 
caspase-3 activation. Therefore, L-arginine plays an 
important role in modulating oxidative stress and 
apoptosis induced by 5-FU. These results were con-
cluded by Thant et al. [43] and Rashid et al. [34] 
who reported that apoptosis elicited by 5-FU is 
a caspase-dependent process that includes activation 
of the initiator active caspase-9 in addition to ef-
fector caspase-3. Many researchers suggested that 
these changes are due to the free radical generation 
released in lipid peroxidation, cell membrane damage 
and apoptosis [46]. 
Several studies proposed a link between the anti-
apoptotic effect of L-arginine was secondary to the 
prevention of the formation of peroxynitrite anions 
in the renal tissue [10, 23, 27].
CONCLUSIONS
In conclusion, administration of L-arginine was 
found to be powerfully protective in the model of ne-
phropathy seen in fluorouracil treated rats. L-arginine 
has a tendency to preserve most of morphological, 
immunohistochemical and biochemical parameters 
towards normal values. Human trials are essential to 
prove this protective role. 
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